FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an antibody which binds specifically to glypican-3. Also disclosed are a nucleic acid coding the above-mentioned antibody; a vector containing the above-mentioned nucleic acid; a host cell containing the above-mentioned vector; an immunoconjugate containing the above-mentioned antibody; and a receptor containing the above-mentioned antibody; a composition containing said antibody. Disclosed is the use of the above-mentioned antibody for the production of a drug with a directed effect.
EFFECT: invention enables effectively treating diseases associated with tumor cells expressing glypican-3.
37 cl, 9 dwg, 6 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| ELEMENTS THAT BIND TO IL-1 BETA | 2013 |
|
RU2711118C2 |
| BISPECIFIC ANTIBODIES BINDING TO TFR | 2019 |
|
RU2810756C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
